Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab-Reference-Cited by-同舟云学术

Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab

Published:2024-04 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Robinson Matthew D.¹^ORCID,Wheatley Roseanna¹²^ORCID,Foster Lucy³,Jamdar Saurabh⁴,Siriwardena Ajith K.⁴^ORCID,Lamarca Angela¹²^ORCID,Hubner Richard¹²,Valle Juan W.¹²^ORCID,McNamara Mairéad G.¹²^ORCID

Affiliation:

1. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, United Kingdom

2. Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, United Kingdom

3. Department of Pathology, Manchester Royal Infirmary, Manchester, United Kingdom

4. Department of Surgery, Manchester Royal Infirmary, Manchester, United Kingdom

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00572

Reference17 articles.

1. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

2. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012

3. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

4. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

5. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial